Consensus on the clinical use of CDK4/6 inhibitors for the treatment of hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer (2023 edition).
10.3760/cma.j.cn112152-20230428-00188
- Collective Name:Breast Cancer Expert Committee of National Tumor Quality Control Center;;Professional Committee on Clinical Research of Tumor Drugs, Chinese Anti-Cancer Association
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
CDK4/6 inhibitor;
Estrogen receptor;
Human epidermal growth factor receptor 2;
Progenstogen receptor
- MeSH:
Humans;
Female;
Breast Neoplasms/pathology*;
Quality of Life;
Consensus;
Triple Negative Breast Neoplasms/drug therapy*;
Receptor, ErbB-2/metabolism*;
Protein Kinase Inhibitors;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Cyclin-Dependent Kinase 4/metabolism*
- From:
Chinese Journal of Oncology
2023;45(12):1003-1017
- CountryChina
- Language:Chinese
-
Abstract:
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have led transformative breakthrough of clinical therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer patients. CDK4/6 inhibitors that have been marketed in China include Ribociclib, Palbociclib, Abemaciclib and Dalpiciclib. For HR-positive HER-2-negative locally advanced and metastatic breast cancer, CDK4/6 inhibitors combined with endocrine therapy have become standard regimen, which can prolong the survival of patients. In the adjuvant treatment stage of early breast cancer, CDK4/6 inhibitors have also achieved positive results and been approved for indications. At present, CDK4/6 inhibitors have been widely used in clinical practice in China. In order to further improve the standardized application of CDK4/6 inhibitors in China, the Breast Cancer Expert Committee of the National Center for Cancer Quality Control and the Professional Committee of Clinical Research of Cancer Drugs of the Chinese Anti-Cancer Association organized the related expert to update the consensus based on the "CDK4/6 inhibitor consensus on clinical application of in the treatment of hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer (2021 edition)" . The updated consensus systematically introduces the pharmacological characteristics, drug monitoring and adverse event management, etc., of CDK4/6 inhibitors to promote the accuracy of clinical decision-making with the ultimate goal to prolong the overall survival of patients and improve the quality of life.
